Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Founded in London, Neo Kuma Ventures specializes in early-stage investments in the psychedelic healthcare sector. The firm manages a portfolio of 12 companies and targets global markets, particularly in Europe. Their average ticket size ranges from £150,000 to £1 million.
Neo Kuma Ventures invests in early-stage companies within the psychedelic healthcare sector, focusing on pre-seed to Series A stages. Their investment strategy includes various categories such as compounds, clinics and care delivery, and digital therapeutics and platforms. The firm aims to support advancements in clinical research and redefine patient care standards.
Notable portfolio companies include Atai Lifescience, Beckley Psytech, Bright Minds, Kanna Health, Small Pharma, Journey Clinical, Wavepaths, Awakn Lifesciences, Sana Health, Monument Therapeutics, Tripp, and Neurocentrx.
Submit your pitch through their website contact form for consideration.
Yes, Neo Kuma Ventures often leads investment rounds in their target sectors, particularly in early-stage companies focused on psychedelic therapies.
The firm is open to follow-on investments, especially for companies that demonstrate significant progress and alignment with their investment thesis.
Specific fund size details are not disclosed, but the firm typically invests between £150,000 and £1 million per company.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.